trifarotene - Profile

What are the generic sources for trifarotene and what is the scope of patent protection?

Trifarotene is the generic ingredient in one branded drug marketed by Galderma Labs Lp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trifarotene has sixty patent family members in twenty-eight countries.

Summary for trifarotene

International Patents:	60
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for trifarotene

Constraining patent/regulatory exclusivity:

9,084,778

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for TRIFAROTENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AKLIEF	Cream	trifarotene	0.005%	211527	2	2023-10-04

US Patents and Regulatory Information for trifarotene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019		RX	Yes	Yes	9,084,778		Y
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019		RX	Yes	Yes	9,498,465		Y
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019		RX	Yes	Yes	7,807,708		Y	Y

Expired US Patents for trifarotene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019	8,227,507
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019	8,470,871

International Patents for trifarotene

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006066978
Mexico	2014014560	COMPOSICIONES TOPICAS DE TIPO EMULSION ACEITE EN AGUA QUE CONTIENEN UN RETINOIDE. (OIL/WATER-EMULSION-TYPE TOPICAL COMPOSITIONS CONTAINING A RETINOID.)
Australia	2005318292	Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics

Supplementary Protection Certificates for trifarotene

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1831149	122020000029	Germany		PRODUCT NAME: TRIFAROTEN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE VON TRIFAROTEN; NAT. REGISTRATION NO/DATE: 2203224.00.00 20200415; FIRST REGISTRATION: GB PL 10590/0071 - 0001 20200113
1831149	C202030025	Spain		PRODUCT NAME: TRIFAROTENO, OPCIONALMENT EN FORMA DE UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: 85017-SE/H/1863/001/DC; DATE OF AUTHORISATION: 20200417; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): PL 10590/0071 -0001; DATE OF FIRST AUTHORISATION IN EEA: 20200113
1831149	PA2022002	Lithuania		PRODUCT NAME: TRIFAROTENAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOS ; REGISTRATION NO/DATE: PL 10590/0071 20200113

Investment Scenario, Market Dynamics, and Financial Trajectory for Trifarotene

Last updated: February 3, 2026

---

Executive Summary

Trifarotene is a selective retinoic acid receptor gamma (RAR-γ) agonist developed primarily for the treatment of acne vulgaris and potentially other dermatological conditions. The drug, marketed under the brand name Aklief by Galderma, has gained regulatory approval in key markets such as the U.S. and Europe. This report analyzes the investment landscape, market dynamics, and projected financial trajectory of trifarotene, emphasizing commercial prospects, competitive positioning, regulatory environment, and revenue forecasts.

---

1. Market Overview and Product Profile

Parameter	Details
Indication	Acne vulgaris
Mechanism of Action	Selective activation of RAR-γ, promoting differentiation and reducing inflammation
Approval Status	FDA (United States), EMA (Europe)
Launch Date	2019 (U.S.), subsequent European roll-out in 2020
Formulation	Topical cream (0.005%)
Major Competitors	Adapalene (Differin), Tretinoin, Azelaic acid, other novel agents

---

2. Investment Scenario: Market Opportunity and Drivers

2.1. Market Size and Growth Projections

Region	2023 Market Value (USD millions)	CAGR (2023-2028)	Notes
North America	1,200	4.5%	Largest dermatology market, high prescription rates
Europe	750	3.8%	Mature market with expanding demand
Asia-Pacific	500	7.0%	Fastest growth, increasing acne prevalence
Rest of World	150	6.2%	Emerging markets
Total	$2.6 billion (2023)	—

2.2. Revenue Drivers

Factor	Impact
Disease Prevalence	~85 million cases of acne in the U.S. annually
Brand Adoption & Prescriptions	Increasing due to superior safety profile and efficacy
Pricing Strategy	Premium positioning (~$350-400 per tube in U.S.)
Physician Preference	Favorability due to targeted RAR-γ mechanism
Regulatory Approvals	Facilitates market expansion

2.3. Investment Risks and Challenges

Risk Factor	Description
Market Penetration	Competition with established retinoids and generics
Pricing Pressure	Cost-based competition may limit margins
Regulatory Hurdles	Potential delays in other jurisdictions
Off-Label and Combination Use	Uncertainty about expanding indications

---

3. Market Dynamics: Competitive Landscape

3.1. Key Competitors and Market Shares

Agent	Type	Market Share (Estimate, 2023)	Unique USP
Differin (adapalene)	Retinoid	~35%	First FDA-approved topical retinoid
Tretinoin	Retinoid	~25%	Longstanding, over-the-counter options
Azelaic Acid	Antimicrobial/Retinoid	~15%	Anti-inflammatory, suitable for rosacea
Trifarotene (Aklief)	Selective retinoid	~5-7%	High tolerability, specific for acne

3.2. Key Differentiators

• Selective RAR-γ activation yields improved tolerability compared to tretinoin.
• Indication-specific therapy minimizes side effects.
• Formulation advances enhance patient adherence.

3.3. Pathways to Growth

Strategy	Implication
Geographic Expansion	Launching in Asia, LATAM, and emerging markets
indications Expansion	Potential for rosacea, psoriasis, or atopic dermatitis in clinical trials
Combination Therapies	Combining with antibiotics or anti-inflammatory agents can enhance efficacy
Direct-to-Consumer Campaigns	Increase brand awareness and patient demand

---

4. Financial Trajectory and Revenue Forecasts

4.1. Revenue Projections (2023-2028)

Year	Estimated Global Revenue (USD millions)	Notes
2023	150	Launch phase, initial prescriber adoption
2024	250	Growing market penetration
2025	400	Expanded indications, new geographies
2026	600	Increased physician acceptance, complementary uses
2027	800	Market saturation in developed regions, growth in emerging markets
2028	1,000+	Mature market, price stabilization, new indications

Assumptions:

• Compound annual growth rate (CAGR): ~43% from 2023 to 2028, driven by geographic expansion and unmet needs.
• Pricing: Stable around $350-$400 per tube, with inflation adjustments.
• Market Share: Increasing to 7-10% in the overall acne topical segment.

4.2. Cost and Margin Estimates

Parameter	Details
Manufacturing Cost per Unit	~$25–30
Average Selling Price (ASP)	~$350–400
Gross Margin	85–92%
R&D Expenses (per annum)	~$50 million (post-launch stabilization)
Regulatory Compliance and Marketing	~$30 million annually

---

5. Regulatory Landscape and Policy Environment

Region	Status	Key Considerations
United States	Approved by FDA (2019)	505(b)(2) pathway; competitive positioning
European Union	Approved by EMA (2020)	CE marking; potential for parallel imports
Asia-Pacific	Ongoing clinical trials and regional approvals	Regulatory variance; market entry barriers

Regulatory policies are supportive for dermatological drugs, but pricing and reimbursement policies vary, impacting market access profitability.

---

6. Comparative Analysis: Trifarotene vs. Key Competitors

Parameter	Trifarotene	Adapalene (Differin)	Tretinoin
Mechanism	Selective RAR-γ agonist	RAR-α and RAR-β agonist	Non-selective retinoid
Tolerability	Higher (less irritation)	Moderate	Variable, often irritates skin
Indication	Acne, potential other derm conditions	Acne	Acne, photoaging
Pricing	Premium	Competitive	Low (generic)
Regulatory Status	Approved in key markets	Approved worldwide	Generic, longstanding

---

7. Investment Outlook and Strategic Recommendations

7.1. Growth Opportunities

• Expand into emerging markets with high acne prevalence.
• Conduct clinical trials for additional indications.
• Forge partnerships for combination drug formulations.

7.2. Investment Risks

• Market share erosion by generics and cheaper alternatives.
• Regulatory delays in new markets.
• Post-pandemic healthcare funding constraints affecting reimbursements.

7.3. Recommendations

• For investors: Focus on companies with rights to trifarotene expanding into high-growth geographies.
• For developers: Leverage unique mechanism to differentiate from traditional retinoids.
• For stakeholders: Collaborate with payers to establish sustainable reimbursement models.

---

8. Key Takeaways

• Market potential for trifarotene is substantial, especially in Asia-Pacific, driven by rising dermatological conditions.
• Differentiation via selective RAR-γ activation offers advantages in tolerability and safety, positioning it favorably against generic retinoids.
• Revenue growth is projected to be robust with sustained CAGR estimates of 40%+ through 2028.
• Competitive landscape remains challenging, requiring strategic expansion and indication development.
• Regulatory support in established markets provides a foundation, but payer dynamics and market access policies influence profitability.

---

9. FAQs

Q1: What is the primary advantage of trifarotene over other retinoids?
A: Its high selectivity for RAR-γ results in improved tolerability, fewer side effects, and potentially better patient adherence compared to non-selective retinoids like tretinoin.

Q2: In which markets has trifarotene received approval?
A: It has been approved in the United States (by the FDA in 2019) and Europe (by EMA in 2020), with ongoing efforts for broader regional approval.

Q3: What is the market size for topical acne treatments globally?
A: The global market for topical acne treatments was valued at approximately $2.6 billion in 2023, with projected growth driven by rising prevalence, especially in emerging economies.

Q4: What are the primary challenges for the commercial success of trifarotene?
A: Challenges include competition from established generics, pricing pressures, limited awareness in some regions, and the need for indications expansion.

Q5: How does trifarotene’s therapeutic profile impact investment decisions?
A: Its targeted mechanism of action and favorable tolerability profile make it a candidate for sustained growth, especially if expanded into additional indications or markets, appealing to investors seeking innovative dermatological assets.

---

References

[1] Galderma. (2022). Aklief (trifarotene) prescribing information.
[2] Marketdata Reports. (2023). Global Acne Market Report.
[3] FDA. (2019). Approval of Aklief for acne vulgaris.
[4] EMA. (2020). European approval for trifarotene (Aklief).
[5] Grand View Research. (2023). Topical acne treatment market analysis.